Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction

被引:21
作者
Kiss, Adam Ferenc [1 ]
Vasko, Dorottya [1 ]
Deri, Mate Tamas [1 ]
Toth, Katalin [1 ]
Monostory, Katalin [1 ]
机构
[1] Hungarian Acad Sci, Res Ctr Nat Sci, Inst Enzymol, Budapest, Hungary
关键词
CYP2C19; genotype; Genetic polymorphism; Phenotype prediction; Personalized medication; PROTON PUMP INHIBITORS; MESSENGER-RNA LEVELS; GENE POLYMORPHISMS; DRUG-METABOLISM; LIVER-DISEASE; PHARMACOGENETICS; CYP2D6; CYP2C19-ASTERISK-17; CYTOCHROME-P450; THERAPY;
D O I
10.1016/j.pharep.2017.12.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: CYP2C19 is an important drug-metabolizing enzyme, responsible for metabolism of approximately 10% of the drugs on the market. Large inter-individual differences exist in metabolic activities, which are primarily attributed to genetic polymorphism of CYP2C19 gene. Conflicting results have been published about the role of CYP2C19 polymorphisms in metabolism of CYP2C19 substrates and clinical outcomes; thus, we aimed to investigate CYP2C19 genotype-phenotype associations, and we sought to elicit potential causes of discrepancies in the genotype-based prediction by incorporating the liver donors' demographic data, drug administration events and pathological conditions. Methods: (S)-Mephenytoin was used to assess CYP2C19 activities in human liver microsomes derived from 114 Hungarian organ donors. CYP2C19 genotype was determined by SNP genotyping for CYP2C19* 2, CYP2C19* 3, CYP2C19* 4 and CYP2C19* 17 variants, and CYP2C19 mRNA levels were measured by qPCR method. Clinical data of the donors were considered in the genotype-based phenotype prediction. Results: CYP2C19 phenotype of 40% of the donors was well-predicted from the genotype data, whereas the phenotype of 13% was underestimated displaying higher activity, and of 47% was overestimated displaying lower activity than predicted from CYP2C19 genotype. Among the donors with overestimated phenotype, one was treated with CYP2C19 substrate/inhibitor, 9 were on amoxicillin-clavulanic acid therapy, 7 were chronic alcohol consumers and 9 had disease with inflammatory processes. Conclusions: CYP2C19 genotype only partially determines the CYP2C19 phenotypic appearance; comedication, diseases with inflammatory processes and aspecific factors, such as chronic alcohol consumption and amoxicillin-clavulanic acid therapy (or any drug therapy resulting in liver injury) seem to be potential phenotype-modifying factors. (c) 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.
引用
收藏
页码:525 / 532
页数:8
相关论文
共 38 条
  • [1] Gene-specific effects of inflammatory Cytokines on cytochrome P4502C, 2B6 and 3A4 mRNA levels in human Hepatocytes
    Aitken, Alison E.
    Morgan, Edward T.
    [J]. DRUG METABOLISM AND DISPOSITION, 2007, 35 (09) : 1687 - 1693
  • [2] Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6
    Bahar, Muh Akbar
    Setiawan, Didik
    Hak, Eelko
    Wilffert, Bob
    [J]. PHARMACOGENOMICS, 2017, 18 (07) : 701 - 743
  • [3] The Transcriptional Regulation of the Human CYP2C Genes
    Chen, Yuping
    Goldstein, Joyce A.
    [J]. CURRENT DRUG METABOLISM, 2009, 10 (06) : 567 - 578
  • [4] Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450
    Chung, WG
    Park, CS
    Roh, HK
    Lee, WK
    Cha, YN
    [J]. JAPANESE JOURNAL OF PHARMACOLOGY, 2000, 84 (02) : 213 - 220
  • [5] Comparison of (S)-mephenytoin and proguanil oxidation in vitro:: contribution of several CYP isoforms
    Coller, JK
    Somogyi, AA
    Bochner, F
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (02) : 158 - 167
  • [6] Acute liver failure due to amoxicillin and amoxicillin/clavulanate
    Fontana, RJ
    Shakil, AO
    Greenson, JK
    Boyd, I
    Lee, WM
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (10) : 1785 - 1790
  • [7] Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations
    Fricke-Galindo, I.
    Cespedes-Garro, C.
    Rodrigues-Soares, F.
    Naranjo, M. E. G.
    Delgado, A.
    de Andres, F.
    Lopez-Lopez, M.
    Penas-Lledo, E.
    LLerena, A.
    [J]. PHARMACOGENOMICS JOURNAL, 2016, 16 (02) : 113 - 123
  • [8] Plasma levels of TNF-α and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure
    Frye, RE
    Schneider, VM
    Frye, CS
    Feldman, AM
    [J]. JOURNAL OF CARDIAC FAILURE, 2002, 8 (05) : 315 - 319
  • [9] Liver disease selectively modulates cytochrome P450-mediated metabolism
    Frye, Reginald F.
    Zgheib, Nathalie K.
    Matzke, Gary R.
    Chaves-Gnecco, Diego
    Rabinovitz, Mordechai
    Shaikh, Obaid S.
    Branch, Robert A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (03) : 235 - 245
  • [10] Pharmacogenomics of proton pump inhibitors
    Furuta, T
    Shirai, N
    Sugimoto, M
    Ohashi, K
    Ishizaki, T
    [J]. PHARMACOGENOMICS, 2004, 5 (02) : 181 - 202